Impact of CMV serostatus on LFS, RI, NRM, OS, chronic GVHD, and neutrophil engraftment
| CMV serostatus . | LFS . | RI . | NRM . | OS . | cGVHD . | NEG . |
|---|---|---|---|---|---|---|
| Total (n = 16 628) | 45 | 32 | 22 | 51 | 45 | 97 |
| D-CMV–/R-CMV– | 49 | 31 | 20 | 56 | 45 | 97 |
| D-CMV+/R-CMV– | 44 | 34 | 22 | 49 | 47 | 96 |
| D-CMV–/R-CMV+ | 43 | 31 | 25 | 49 | 44 | 96 |
| D-CMV+/R-CMV+ | 45 | 33 | 23 | 51 | 44 | 96 |
| P | < .001 | .11 | < .001 | < .001 | .63 | < .001 |
| D-CMV–/R-CMV– | 49 | 31 | 20 | 56 | 45 | 97 |
| Other combination | 44 | 32 | 23 | 50 | 45 | 96 |
| P | < .001 | .08 | < .001 | < .001 | .6 | .08 |
| CMV serostatus . | LFS . | RI . | NRM . | OS . | cGVHD . | NEG . |
|---|---|---|---|---|---|---|
| Total (n = 16 628) | 45 | 32 | 22 | 51 | 45 | 97 |
| D-CMV–/R-CMV– | 49 | 31 | 20 | 56 | 45 | 97 |
| D-CMV+/R-CMV– | 44 | 34 | 22 | 49 | 47 | 96 |
| D-CMV–/R-CMV+ | 43 | 31 | 25 | 49 | 44 | 96 |
| D-CMV+/R-CMV+ | 45 | 33 | 23 | 51 | 44 | 96 |
| P | < .001 | .11 | < .001 | < .001 | .63 | < .001 |
| D-CMV–/R-CMV– | 49 | 31 | 20 | 56 | 45 | 97 |
| Other combination | 44 | 32 | 23 | 50 | 45 | 96 |
| P | < .001 | .08 | < .001 | < .001 | .6 | .08 |
Two-year probabilities (%; standard error ± 1 for all parameters) are shown.
cGVHD, chronic GVHD; NEG, neutrophil engraftment.